logo

For the Inventor, By the Inventor

Plan-les-Ouates, Switzerland

Obseva S.a.

Calculating rank
USPTO Granted Patents = 11



Trademarks = 9

Forward Citations = 27

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Andre Chollet (7 out of 7 patents)

silverMedal Oliver Pohl (5 out of 7 patents)

bronzeMedal Catherine Jorand-LeBrun (2 out of 17 patents)

4.  Matthias Schwarz (2 out of 35 patents)

5.  André Chollet (2 out of 2 patents)

6.  Ernest Loumaye (2 out of 12 patents)

7.  Vincent Pomel (2 out of 22 patents)

8.  Patrick Naxos Page (2 out of 26 patents)

9.  Anna Quattropani (2 out of 58 patents)

10.  Jean-Pierre Gotteland (2 out of 20 patents)

11.  Catherine Jorand-Lebrun (23 patents)

12.  Jean-Pierre Gotteland (2 patents)

13.  Olivier Pohl (0 patent)

14.  Olivier Pohl (0 patent)

15.  Olivier Pohl (0 patent)


11 patents:

1. 11524003 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2022-12-13),
2. 11419851 - Oral formulations of pyrrolidine derivatives (2022-08-23),
3. 11312683 - Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists (2022-04-26),
4. 10752583 - Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same (2020-08-25),
5. 10604482 - Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists (2020-03-31),
6. 10555934 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2020-02-11),
7. 10478420 - Oral formulations of pyrrolidine derivatives (2019-11-19),
8. 10047048 - Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists (2018-08-14),
9. 9962367 - Oral formulations of pyrrolidine derivatives (2018-05-08),
10. 9718772 - Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same (2017-08-01),
11. 9670155 - Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists (2017-06-06),
Company Overview
Obseva S.A. is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, focused on developing innovative therapies for women's reproductive health. The organization specializes in addressing unmet medical needs in areas such as fertility, pregnancy, and gynecological disorders. By leveraging advanced research and development capabilities, Obseva aims to create effective solutions that enhance the quality of life for women globally, positioning itself as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

11 Patents

#8 in Plan-les-Ouates

#1,041 in Switzerland

#51,831 in the World

Plan-les-Ouates, CH
Plan-les-Ouates, Switzerland

Obseva S.a.

Forward Citations = 27

11 inventors:

goldMedal Andre Chollet (7 out of 7 patents)

silverMedal Oliver Pohl (5 out of 7 patents)

bronzeMedal Catherine Jorand-LeBrun (2 out of 17 patents)

4.  Matthias Schwarz (2 out of 35 patents)

5.  André Chollet (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Obseva S.a.. Retrieved from https://idiyas.com/company/obseva-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…